Revance Therapeutics (NASDAQ:RVNC) received a $55.00 price target from analysts at Cowen in a report issued on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cowen’s price target would indicate a potential upside of 62.96% from the company’s previous close.

Several other equities analysts have also commented on the stock. Cantor Fitzgerald set a $50.00 target price on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 5th. Guggenheim initiated coverage on shares of Revance Therapeutics in a report on Tuesday, December 5th. They issued a “buy” rating and a $42.00 target price on the stock. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, September 19th. Mizuho initiated coverage on shares of Revance Therapeutics in a report on Thursday, November 16th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $28.00 target price on shares of Revance Therapeutics in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $44.30.

Shares of Revance Therapeutics (RVNC) traded up $0.20 during trading on Wednesday, reaching $33.75. 252,300 shares of the company’s stock traded hands, compared to its average volume of 422,275. Revance Therapeutics has a twelve month low of $18.00 and a twelve month high of $37.45. The firm has a market cap of $1,200.21, a PE ratio of -8.88 and a beta of 1.62.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter last year, the firm earned ($0.64) EPS. Revance Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts anticipate that Revance Therapeutics will post -3.74 earnings per share for the current fiscal year.

In related news, CFO Lauren P. Silvernail sold 10,000 shares of Revance Therapeutics stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $26.83, for a total transaction of $268,300.00. Following the sale, the chief financial officer now directly owns 59,006 shares of the company’s stock, valued at approximately $1,583,130.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total transaction of $189,544.00. Following the sale, the chief executive officer now directly owns 133,188 shares in the company, valued at $3,321,708.72. The disclosure for this sale can be found here. Insiders own 18.86% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Pura Vida Investments LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at approximately $1,378,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Revance Therapeutics by 4.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 117,258 shares of the biopharmaceutical company’s stock valued at $3,231,000 after purchasing an additional 5,501 shares during the last quarter. EAM Investors LLC grew its holdings in shares of Revance Therapeutics by 113.9% during the 3rd quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock valued at $1,998,000 after purchasing an additional 38,621 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at approximately $144,000. Finally, Alps Advisors Inc. grew its holdings in shares of Revance Therapeutics by 11.1% during the 3rd quarter. Alps Advisors Inc. now owns 30,351 shares of the biopharmaceutical company’s stock valued at $836,000 after purchasing an additional 3,027 shares during the last quarter. 76.69% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2018/01/19/cowen-analysts-give-revance-therapeutics-rvnc-a-55-00-price-target.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.